BC Innovations | Feb 20, 2019
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting DGAT1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, levels of DGAT1 were higher in CD4 + T cells from the...
BC Week In Review | Oct 5, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for...
BC Extra | Oct 3, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for...
BC Week In Review | May 26, 2014
Company News

Ligand, Viking Therapeutics deal

Ligand granted Viking Therapeutics exclusive, worldwide rights to five therapeutic programs, including two clinical-stage compounds. The deal includes VK0612 (formerly MB07803 ), a fructose 1,6-bisphosphatase inhibitor in Phase II testing to treat Type II diabetes;...
BC Extra | May 23, 2014
Company News

Ligand licenses five programs to Viking

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Viking Therapeutics Inc. (San Diego, Calif.) exclusive, worldwide rights to five therapeutic programs, including two clinical-stage compounds, one preclinical compound, and two portfolios of preclinical compounds. The clinical programs are:...
BioCentury | Apr 28, 2014
Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
BC Week In Review | Aug 12, 2013
Clinical News

P7435: Phase I start

This quarter, Piramal will begin a double-blind, placebo-controlled, crossover, 2-part U.S. Phase I trial to evaluate P7435 in about 122 healthy, overweight or obese subjects. The first portion will evaluate single ascending-doses of P7435. The...
BC Innovations | Feb 9, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Dyslipidemia Diacylglycerol O-acyltransferase-1 (DGAT1) Rodent and cell culture studies suggest the DGAT1 inhibitor ABT-046 could help treat dyslipidemia. In a human cell line, ABT-046...
BioCentury | Aug 22, 2011
Product Development

Beta testing GPR40

With concerns about cardiovascular safety and cancer signals dampening optimism about the future of diabetes therapies, there is an emerging race to demonstrate that activating free fatty acid receptor 1 can avoid such safety issues...
BC Innovations | Oct 28, 2010
Cover Story

DGAT out of the bag

U.S. and French researchers have shown that DGAT1 , an enzyme involved in lipid droplet biogenesis, is a host factor for HCV infection. 1 The results have prompted Via Pharmaceuticals Inc. to consider repurposing its DGAT1...
Items per page:
1 - 10 of 22